stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) Net income
Genmab A/S Sponsored ADR's net income for fiscal 2025 was $1.2B, down 9.20% from $1.3B in fiscal 2024. Over the twelve months to 30 June 2026 it was $906.0M. Over the past ten years it has ranged from $0.00 (fiscal 2017) to $1.3B (fiscal 2024); the current reading is higher than 90% of that period. Genmab A/S Sponsored ADR ranks 8th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $1.2B | (9.20%) |
| FY2024 | $1.3B | 62.01% |
| FY2023 | $818.5M | (17.83%) |
| FY2022 | $996.2M | 57.20% |
| FY2021 | $633.7M | (29.94%) |
| FY2020 | $904.5M | 111.05% |
| FY2019 | $428.6M | 67.84% |
| FY2018 | $255.3M | — |
| FY2017 | $0.00 | — |
| FY2016 | $168.4M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $295.0M | 298.65% |
| Mar 2026 | $74.0M | 34.55% |
| Dec 2025 | $55.0M | (88.59%) |
| Sep 2025 | $482.0M | 13.95% |
| 27 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $2.6B |
| RPRX Royalty Pharma PLC compare | $1.3B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $915.6M |
| GMAB Genmab A/S Sponsored ADR | $906.0M |
| INCY Incyte Corporation compare | $403.4M |
| ROIV Roivant Sciences Ltd. compare | −$414.6M |
| INSM Insmed, Inc. compare | −$605.6M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.6B |
| RVMD Revolution Medicines, Inc. compare | −$1.9B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on GMAB
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement